Controversies related to renal artery denervation and devices

• Published in: Current opinion in cardiology Vol. 39; no. 4; pp. 244 - 250
• Main Authors: Agwuegbo, Chibuike Charles, Antia, Akanimo Usen, Shamaki, Garba Rimamskep, Bob-Manuel, Tamunoinemi
• Format: Journal Article
• Language: English
• Published: United States 01-07-2024
• Subjects: Blood Pressure - physiology; Catheter Ablation - methods; Humans; Hypertension - surgery; Renal Artery - innervation; Sympathectomy - methods
• ISSN: 0268-4705; 1531-7080
• DOI: 10.1097/HCO.0000000000001146

This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention.
There have been conflicting data from the different randomized control trials assessing the efficacy of renal artery denervation in the management of resistant hypertension.
Renal artery denervation is achieved by ablating the sympathetic nerves surrounding the renal arteries using endovascular ultrasound, radiofrequency, or alcohol. Our review article highlights that renal artery denervation is generally effective in improving blood pressure in patients with resistant hypertension. The Food and Drug Administration (FDA) has recently approved the ReCor Medical Paradise system, and the Symplicity Spyral RDN systems for renal artery denervation.